EAY131-Z1H, NCT06400238: Testing Copanlisib as Potentially Targeting Treatment in Cancers With PTEN Expression (MATCH - Subprotocol Z1H) |
|
|
| Active, not recruiting | 2 | 35 | US | Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Copanlisib, BAY 80 6946, BAY 80-6946, BAY 806946, BAY-80-6946, BAY806946, PI3K Inhibitor BAY 80-6946, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI | National Cancer Institute (NCI) | Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma | 05/25 | 05/25 | | |
EAY131-P, NCT04439188: Testing GSK2636771 as a Potential Targeted Treatment in Cancers With PTEN Loss of Expression (MATCH-Subprotocol P) |
|
|
| Active, not recruiting | 2 | 35 | US | PI3K-beta Inhibitor GSK2636771, GSK-2636771, GSK2636771 | National Cancer Institute (NCI) | Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma | 11/25 | 11/25 | | |
EAY131-N, NCT04439149: Testing GSK2636771 as a Potential Targeted Treatment in Cancers With PTEN Genetic Changes (MATCH-Subprotocol N) |
|
|
| Active, not recruiting | 2 | 35 | US | PI3K-beta Inhibitor GSK2636771, GSK-2636771, GSK2636771 | National Cancer Institute (NCI) | Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma | 11/25 | 11/25 | | |
NCT04171219: Talabostat and Pembrolizumab for the Treatment of Advanced Solid Cancers |
|
|
| Active, not recruiting | 2 | 15 | US | Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475, Talabostat Mesylate, Val-boro-Pro | M.D. Anderson Cancer Center, National Cancer Institute (NCI) | Advanced Malignant Solid Neoplasm, Recurrent Malignant Solid Neoplasm | 04/25 | 04/25 | | |
NCT01087554: Sirolimus or Everolimus or Temsirolimus and Vorinostat in Advanced Cancer |
|
|
| Active, not recruiting | 1 | 249 | US | Sirolimus, Rapamune, Vorinostat, SAHA, Suberoylanilide Hydroxamic Acid, MSK-390, Zolinza, Everolimus, Afinitor, Zortress, RAD001, Temsirolimus, CCI-779, Torisel | M.D. Anderson Cancer Center | Advanced Cancer | 08/26 | 08/26 | | |
